Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest PDE5 inhibitors Stories

2012-02-10 07:36:00

FORT LAUDERDALE, Fla., Feb. 10, 2012 /PRNewswire/ -- In an effort to raise awareness of the prevalence of Erectile Dysfunction (ED), Nouveau Life Pharmaceuticals (soon to be changed from Hybrid Fuels, Inc., Pink Sheets: HRID) provides its customers published statistics regarding ED and the benefits of Azul Instant(TM) as an all-natural alternative to those suffering with the condition. Experts report that 30 million men in the United States have ED and one in 10 men in the world suffers...

2012-02-09 20:00:00

NEW YORK, Feb. 9, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at BioSante Pharmaceuticals, Inc. ("BioSante" or the "Company") (Nasdaq: BPAX). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) BioSante's LibiGel product was ineffective and failed to deliver...

2012-02-07 07:00:00

INDIANAPOLIS, Feb. 7, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that a Phase III study, published online by European Urology, showed both Cialis® (tadalafil) and tamsulosin significantly improved scores on the International Prostate Symptom Score (IPSS), compared to placebo, in men with signs and symptoms suggestive of benign prostatic hyperplasia (BPH). Cialis improved erectile dysfunction (ED) in those men who had both signs and symptoms of BPH...

2012-01-22 08:00:00

It´s always amazing how fast money leaves the bank account around the holidays. Now that the presents are unwrapped and the New Year´s party is over, it may seem like the wallet is a little lighter than it should be. AccessRx.com, a top-ranked prescription drug facilitator, is here to combat the spending blues and ring in the New Year by offering free shipping on all medications. Tempe, AZ (PRWEB) January 22, 2012 It´s always amazing how fast money leaves the bank account...

2012-01-17 06:00:00

GREENWOOD VILLAGE, Colo., Jan. 17, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced notification by the European Patent Office they will be awarded two new patents in Europe for the combination of Zertane(TM) (Ampio's premature ejaculation (PE) drug) with any erectile dysfunction (ED) drug of the PDE5...

2012-01-17 05:45:00

MOUNTAIN VIEW, Calif., Jan. 17, 2012 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that results from the REVIVE study were published in The Journal of Sexual Medicine (JSM), a peer-reviewed journal with broad, multidisciplinary readership. REVIVE (TA-301) was a randomized, placebo-controlled, phase 3 study evaluating the safety and efficacy of avanafil, an investigational drug currently under review by the Food and Drug Administration (FDA) for the treatment of erectile...

2011-12-23 11:04:48

Circulation: active ingredient sildenafil makes stiffened cardiac walls elastic again How sildenafil, the active ingredient in Viagra, can alleviate heart problems is reported by Bochum's researchers in cooperation with colleagues from the Mayo Clinic in Rochester (Minnesota) in the journal Circulation. They studied dogs with diastolic heart failure, a condition in which the heart chamber does not sufficiently fill with blood. The scientists showed that sildenafil makes stiffened cardiac...

2011-12-05 05:45:00

MOUNTAIN VIEW, Calif., Dec. 5, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts were presented over the weekend at the 2011 European Society of Sexual Medicine (ESSM) Meeting in Milan, Italy. The ESSM is the largest gathering of medical professionals specializing in sexual dysfunction and treatment in Europe. The specific abstracts that were presented on December 3rd, 2011 include: A moderated poster presentation by Laurence...

2011-11-14 05:45:00

MOUNTAIN VIEW, Calif., Nov. 14, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that new analyses from TA-314, a phase 3 long-term safety and efficacy study of the investigational drug avanafil for the treatment of erectile dysfunction (ED), was presented over the weekend at the 2011 Sexual Medicine Society of North America (SMSNA) Meeting in Las Vegas, NV. Andrew R. McCullough, MD, Professor of Surgery/Urology at Albany Medical College, presented the analysis of results...

2011-11-10 05:45:00

MOUNTAIN VIEW, Calif., Nov. 10, 2011 /PRNewswire/ -- Highlights from Avanafil Development Program Include: Early onset of action observed in placebo-controlled trials Comparative in-vitro selectivity of avanafil, sildenafil, vardenafil and tadalafil Safety and efficacy in post-prostatectomy population VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts will be presented at the Sexual Medicine Society of North America (SMSNA) on November 12, 2011 in Las Vegas, NV. The...